Edap Tms (NASDAQ:EDAP) Share Price Passes Above 200 Day Moving Average - Here's What Happened

Key Points

• Shares passed above the 200‑day moving average, trading as high as $3.35 versus the 200‑day average of $3.29 and last at $3.22 on volume of 6,259 shares.
• Analyst consensus is lukewarm: one Buy, two Hold and one Sell produce an average rating of "Hold" and a $6 average price target, with recent notes including a Weiss Sell, a Wall Street Zen downgrade to Sell, and HC Wainwright cutting its target from $14 to $10 (still Buy).
• Fundamentals show pressure: the company reported Q1 EPS of -$0.25 (missed est. -$0.16) while revenue of $22.22M beat estimates; Edap has negative margins/ROE, a market cap of about $121M and roughly 63% institutional ownership.

Shares of Edap Tms S.A. (NASDAQ:EDAP - Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.29 and traded as high as $3.35. Edap Tms shares last traded at $3.22, with a volume of 6,259 shares trading hands.

Analyst Ratings Changes

Several brokerages recently issued reports on EDAP. Weiss Ratings reiterated a "sell (d-)" rating on shares of Edap Tms in a research report on Monday, December 29th. Wall Street Zen cut Edap Tms from a "hold" rating to a "sell" rating in a research note on Saturday, March 28th. Finally, HC Wainwright cut their target price on Edap Tms from $14.00 to $10.00 and set a "buy" rating on the stock in a research note on Thursday, April 9th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $6.00.

Edap Tms Stock Performance

The firm has a market capitalization of $120.69 million, a price-to-earnings ratio of -4.18 and a beta of -0.09. The company has a fifty day moving average of $3.88 and a two-hundred day moving average of $3.29. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.19 and a current ratio of 1.54.

Edap Tms (NASDAQ:EDAP - Get Free Report) last released its quarterly earnings results on Wednesday, March 25th. The medical equipment provider reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.09). The firm had revenue of $22.22 million for the quarter, compared to analyst estimates of $21.28 million. Edap Tms had a negative return on equity of 100.07% and a negative net margin of 41.24%. As a group, equities research analysts predict that Edap Tms S.A. will post -0.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Edap Tms

Hedge funds have recently added to or reduced their stakes in the stock. Financial Planning Navigators CORP bought a new position in Edap Tms during the 4th quarter worth $33,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Edap Tms in the 1st quarter valued at $38,000. Kovack Advisors Inc. acquired a new stake in shares of Edap Tms in the 4th quarter valued at $53,000. Leonteq Securities AG acquired a new stake in shares of Edap Tms in the 4th quarter valued at $313,000. Finally, Flax Pond Capital LLC acquired a new stake in shares of Edap Tms in the 4th quarter valued at $2,623,000. Institutional investors own 62.74% of the company's stock.

Edap Tms Company Profile

Edap Tms SA NASDAQ: EDAP is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm's core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms's Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.